" class="no-js "lang="en-US"> Everest Medicines Partners with Shanghai Pharma Subsidiary
Monday, April 15, 2024

Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that it has signed a Memorandum of Understanding for a strategic partnership with a subsidiary of Shanghai Pharma, SPH Keyuan Xinhua Pharmaceutical. According to the MoU, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline) in China. SPH Kyuan’s leading position in drug import, nationwide distribution network, and modern logistics system will help expand the scale and speed of commercialization of XERAVA to benefit patients and address urgent unmet needs in the country.

XERAVA was approved by the National Medical Products Administration (“NMPA”) of China for the treatment of complicated intra-abdominal infections (“cIAI”) in adult patients in March 2023, and has been recommended by multiple treatment guidelines in China and globally with its broad bacterial spectrum coverage and high potency against multidrug-resistant bacterial infections. Everest plans to commercially launch XERAVA in mainland China in the third quarter of this year.

“We are very excited to reach a partnership with SPH Kyuan. SPH Kyuan’s rich experience in drug import and channel distribution will accelerate the delivery of XERAVA to hospitals and patients in need,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “This partnership marks another step towards the successful commercialization of XERAVA, leading our pipeline with at least three more products expected to be approved in the next two years.”

“Everest Medicines has very promising market potential in the fields of anti-infectious and renal diseases. We are honored to reach a strategic pact with Everest around XERAVA, which will leverage the strengths of both parties,” said Yu Rui, general manager of SPH Kyuan. “We look forward to continued partnership with Everest to bring more novel products to patients in need.”

“Drug-resistant bacteria infections is a severe problem both in China and overseas, creating both economic and healthcare burdens, and carbapenem-resistant gram-negative organisms are the focus of global attention. Due to the complex mechanism of carbapenem-resistant gram-negative organisms, it has been challenging to develop new drugs for use in clinical treatment,” said Wang Hui, Deputy Director, Chief Physician at the Department of Infectious Diseases, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, and Chairman-elect of Infectious Diseases Branch of Shanghai Medical Association. “Existing treatment options in China cannot meet clinical needs, and innovative drugs with broad bacterial spectrum coverage and high antibacterial potency such as XERAVA are urgently needed to cope with the challenges from drug-resistant infections”.

In addition to XERAVA, Everest is also actively developing other critical innovative treatment options in the infectious disease space, including taniborbactam which we plan to file for NDA in China this year for complicated urinary tract infection, and EVER206, a novel polymyxin derivative with potentially robust safety profile, which is expected to initiate phase III clinical study in the second half of this year.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more